Company: APM
Filing Date: 2025-07-15
Form Type: DRS
Source: 0001213900-25-063899
Chunk: 388

Company: Aptorum Group Ltd
Filing Date: 2025-07-15
Form: DRS
Chunk 388
---
 “incorporate by reference” the information we file with
it, which means that we can disclose important information to you by referring you to those documents instead of having to repeat the
information in this prospectus. Any statement contained in any document incorporated or deemed to be incorporated by reference herein
shall be deemed to be modified or superseded for purposes of this prospectus to the extent that a statement contained in or omitted from
this prospectus or any accompanying prospectus supplement, or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein,
modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded,
to constitute a part of this prospectus.

This prospectus incorporates by reference the documents listed below:

| (1) | the                                                                                                                                       
 Company’s Annual Report on Form 20-F for the fiscal year ended December 31, 2024, filed with the SEC on April 30, 2025, which             
 contains our audited consolidated financial statements for the most recent fiscal year for which those statements have been filed;        |
| (2) | the                                                                                                                                       
 description of our Ordinary Shares contained in our Registration Statement on Form 8-A filed with the SEC on December 14, 2018, including 
 any amendments and reports filed for the purpose of updating such description.                                                            |

We will provide a copy of
the documents we incorporate by reference, at no cost, to any person who receives this prospectus. To request a copy of any or all of
these documents, you should write or telephone us at 17 Hanover Square, London W1S 1BN, United Kingdom, Attention: Ian Huen, Chief Executive
Officer, +44 20 80929299. Additionally, copies of the documents incorporated herein by reference may be accessed at our website at www.aptorumgroup.com.
The reference to our website address does not constitute incorporation by reference of the information contained on or accessible through
our website, and you should not consider the contents of our website in making an investment decision with respect to our Class A Ordinary
Shares.

<div align='center'>210

UNAUDITED PRO FORMA CONSOLIDATED COMBINED FINANCIAL INFORMATION</div>

On July 14, 2025, Aptorum Group Limited (the “Company”),
entered into a Merger Agreement with DiamiR Biosciences Corp. encompassing a license